We are live on ! Find out more
RCEL icon

Avita Medical

80 hedge funds and large institutions have $119M invested in Avita Medical in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 32 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.81% more ownership

Funds ownership: 30.05%31.86% (+1.8%)

5% more call options, than puts

Call options by funds: $563K | Put options by funds: $535K

0% more funds holding

Funds holding: 8080 (0)

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

8% less capital invested

Capital invested by funds: $129M → $119M (-$10.7M)

31% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 32

Holders
80
Holders Change
Holders Change %
0%
% of All Funds
1.27%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
22
Reduced
32
Closed
10
Calls
$563K
Puts
$535K
Net Calls
+$28K
Net Calls Change
-$75K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$25.1M +$791K +46,718 +3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$19.9M +$187K +11,062 +0.8%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$7.29M +$397K +23,461 +5%
DCM
4
Driehaus Capital Management
Illinois
$7.24M +$8.39M +495,768 New
PVI
5
Pura Vida Investments
New York
$7.02M +$919K +54,322 +13%
State Street
6
State Street
Massachusetts
$6.85M +$286K +16,912 +4%
Russell Investments Group
7
Russell Investments Group
United Kingdom
$5.38M +$2.59M +152,947 +71%
EI
8
EAM Investors
California
$3.64M +$1.28M +75,436 +43%
Northern Trust
9
Northern Trust
Illinois
$3.19M +$11.8K +700 +0.3%
Calamos Advisors
10
Calamos Advisors
Illinois
$3.08M +$2.12M +125,010 +146%
Morgan Stanley
11
Morgan Stanley
New York
$2.32M +$2.07M +122,565 +340%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$1.87M +$196K +11,571 +10%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$1.68M -$617K -36,488 -24%
Ameriprise
14
Ameriprise
Minnesota
$1.67M -$4.33K -256 -0.2%
Point72 Asset Management
15
Point72 Asset Management
Connecticut
$1.41M +$1.63M +96,433 New
Two Sigma Advisers
16
Two Sigma Advisers
New York
$1.33M -$399K -23,600 -21%
Two Sigma Investments
17
Two Sigma Investments
New York
$1.19M -$1.06M -62,717 -43%
GC
18
Globeflex Capital
California
$1.12M -$632K -37,361 -33%
SCM
19
Soleus Capital Management
Connecticut
$1.1M
N
20
Nuveen
North Carolina
$1.05M -$224K -13,260 -16%
Renaissance Technologies
21
Renaissance Technologies
New York
$1.04M -$487K -28,800 -29%
Charles Schwab
22
Charles Schwab
California
$1.01M +$25.5K +1,507 +2%
Assenagon Asset Management
23
Assenagon Asset Management
Luxembourg
$984K -$400K -23,620 -26%
1CM
24
1492 Capital Management
Wisconsin
$903K +$1.05M +61,782 New
Bank of America
25
Bank of America
North Carolina
$887K -$188K -11,096 -15%

RCEL Hedge Fund Activity: Q3 2023 in Review

80 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Avita Medical (RCEL) for Q3 2023, worth a combined $119M — down 8.3% from $129M a quarter earlier.

Fund positioning in RCEL was balanced in Q3 2023: 10 funds opened new positions, 10 closed out, 22 added to existing stakes and 32 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $8.39M. The largest seller was Millennium Management, cutting an estimated $4.29M.

  • 80 institutional investors held Avita Medical (RCEL) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $119M of Avita Medical stock for Q3 2023, down 8.3% quarter-over-quarter.
  • 10 funds opened new Avita Medical positions in Q3 2023 and 10 closed out, a net change of 0 holders.
  • The largest Avita Medical buyer in Q3 2023 was Driehaus Capital Management, an estimated $8.39M added.
  • The largest Avita Medical seller in Q3 2023 was Millennium Management, an estimated $4.29M sold.

Based on aggregated 13F filings for Q3 2023.